Core C: Comparative Pathology Core

项目摘要 对所有四个项目中包括的临床前动物模型的研究对于研究 质子/碳粒子闪光放射治疗优于标准粒子的总体假设 放射治疗在保护正常组织的同时保持同等的恶性生长控制。这个 在这些实验环境中外推稳健的临床前数据在很大程度上依赖于无偏见的 评估特定组织病理学参数以研究闪光颗粒的生物学效应 指定肿瘤性病变及邻近病变的放射治疗与标准粒子放射治疗的比较 正常组织。比较病理学核心(CPC；核心C)将提供其专业知识，为 中包括的动物实验的病理终点的计划、评估和解释 项目。作为PennVet临床实验室，Core C严格遵循标准化的工作规程 QA/QC程序。由Core C提供的组织病理学服务将确保准确的收集，适当的 动物标本的保存、及时处理和染色。核心C将提供必要的 组织样本的技术支持和提交将按照优先顺序进行。除了标准 组织病理学，Core C还将开发和验证量身定做的方法来调查和量化组织 与RT特别相关的变化，如纤维化、炎症/免疫细胞在肿瘤内的分布 种群、评估上皮屏障完整性的标志的表达等。委员会认证的兽医 Core C的病理学家将对病理终点进行专家评估和公正的解释。 客观和可重复地量化组织变化对不同放射治疗模式的反应将是 由经过验证的评分系统的应用和基于软件的算法的使用保证 用于数字病理和图像分析。核心病理学家接受了数字影像病理学方面的高级培训 来自徕卡病理系统。此外，阿森马赫博士还与徕卡合作开发了 分析工具，让他在数字病理系统的分析模块方面有了特殊的经验。

Project Summary The study of the preclinical animal models included in all four Projects plays a critical role to investigate the overall hypothesis that Proton/Carbon Particle FLASH Radiotherapy is superior to Standard Particle Radiotherapy in protecting normal tissues while maintaining equipotent malignant growth control. The extrapolation of robust preclinical data in these experimental settings relies heavily on the unbiased assessment of specific histopathological parameters to investigate the biological effects of FLASH particle radiotherapy as compared to Standard particle radiotherapy on designated neoplastic lesions and adjacent normal tissues. The Comparative Pathology Core (CPC; Core C) will provide its expertise contributing to the planning, evaluation, and interpretation of the pathology endpoints of the animal experiments included in the Projects. As a PennVet clinical laboratory, Core C importantly follows standardized working protocols with strict QA/QC procedures. The histopathology service offered by Core C will ensure accurate collection, proper preservation, timely processing, and staining of the animal specimens. Core C will provide the necessary technical support and submissions of tissue samples will follow a prioritized route. In addition to standard histopathology, Core C will also develop and validate tailored approaches to investigate and quantify tissue changes specifically associated with RT such as fibrosis, intralesional distribution of inflammatory/immune cell populations, expression of markers to evaluate epithelial barrier integrity, etc. The board-certified veterinary pathologists of Core C will deliver expert evaluation and unbiased interpretation of the pathology endpoints. Objective and reproducible quantification of tissue changes in response to the diverse RT modalities will be guaranteed by the application of validated scoring systems and the utilization of software-based algorithms for digital pathology and image analysis. Core pathologists have advanced training in digital imaging pathology from Leica pathology systems. Moreover, Dr. Assenmacher has collaborated with Leica in the development of analysis tools, lending him particular experience in the analytic modules of the digital pathology system.